29 October 2026
: Case report
[In Press] Persistent Unexplained CA125 and CA19-9 Elevation During Gynecological Follow-Up: A Diagnostic Challenge Beyond Tumor Marker Non-Specificity
Challenging differential diagnosis, Unusual setting of medical care, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Akina Nigi1ABCD, Noritaka Miya2D, Keisuke Iwamoto2E, Hirohiko Tanaka1FDOI: 10.12659/AJCR.954384
Am J Case Rep In Press; DOI: 10.12659/AJCR.954384
Available online: 2026-10-29, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Tumor marker elevation during surveillance after borderline ovarian tumor surgery commonly raises concern for recurrence. However, CA125 and CA19-9 are nonspecific and may also increase in extrapelvic inflammatory disease.
CASE REPORT
A 66-year-old woman underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and partial rectal resection for bilateral serous borderline ovarian tumor, International Federation of Gynecology and Obstetrics stage IB. Tumor marker levels remained normal for several years after surgery. Eight years later, CA125 increased to 65 U/mL and CA19-9 to 140.5 U/mL, with CA19-9 subsequently peaking at 610 U/mL. Repeated pelvic magnetic resonance imaging, PET-CT, cytologic assessment of the vaginal cuff, upper gastrointestinal endoscopy, and hepatobiliary and pancreatic evaluation showed no evidence of recurrent borderline ovarian tumor or other malignancy. During the same period, interstitial lung disease progressed radiologically, respiratory symptoms worsened, and serologic testing demonstrated myeloperoxidase-antineutrophil cytoplasmic antibody positivity. Progressive myeloperoxidase-antineutrophil cytoplasmic antibody-associated interstitial lung disease was considered a plausible extrapelvic explanation for the persistent marker elevation. Pirfenidone and low-dose prednisolone were initiated, and although tumor marker levels initially continued to rise, they subsequently decreased from their peak values during follow-up while repeated gynecologic evaluation remained negative.
CONCLUSIONS
This case highlights a potential limitation in the interpretation of tumor marker elevation during borderline ovarian tumor surveillance. Persistent CA125 and CA19-9 elevation does not necessarily indicate gynecologic recurrence when repeated pelvic evaluation is negative. In selected patients, pulmonary or systemic inflammatory disease may be considered according to symptoms, imaging findings, and overall clinical context.
Keywords: Lung Diseases; Ovary; Gynecology; Vasculitis
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954600
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954889
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.954405
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.953611
Most Viewed Current Articles
07 Dec 2021 : Case report
28,714,025
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
181,538
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
125,043
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
08 May 2026 : Case report
97,330
DOI :10.12659/AJCR.952158
Am J Case Rep 2026; 27:e952158






